started · updated
Enfortumab Vedotin‑Pembrolizumab Combo Boosts Survival in Muscle‑Invasive Bladder Cancer
The international phase III KEYNOTE‑B15/EV‑304 trial, involving 808 patients with muscle‑invasive bladder cancer, compared a neoadjuvant regimen of the antibody‑drug conjugate enfortumab vedotin combined with the PD‑1 inhibitor pembrolizumab against the standard cisplatin‑based chemotherapy (cisplatin + gemcitabine).
At two‑year follow‑up, event‑free survival was 79.4 % in the enfortumab‑vedotin/pembrolizumab arm versus 66.2 % with chemotherapy, reflecting a 47 % reduction in the risk of recurrence, progression or death. Overall survival also favored the experimental combination, with 86.9 % of patients alive after two years compared with 81.3 % in the control group. The results, presented in the New England Journal of Medicine, were reported by Dr Maria Kaparelou and Prof Thanos Dimopoulos of the Alexandra Hospital, Medical School of the University of Athens (EKPA).
Entities
Dr Maria Kapareli · Dr. Maria Kaparelou · Enfortumab vedotin · Enfortumab vedotin · KEYNOTE‑B15/EV‑304 · KEYNOTE‑B15/EV‑304 study · Muscle‑invasive bladder cancer · Pembrolizumab · Pembrolizumab · Prof. Thanos Dimopoulos
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] Two‑year overall survival was 86.9 % with the combination therapy versus 81.3 % with chemotherapy. www.iatronet.gr · www.zougla.gr
- [● 3 SOURCES] Patients were randomized to receive enfortumab vedotin plus pembrolizumab before cystectomy or standard neoadjuvant chemotherapy with cisplatin and gemcitabine. www.ygeiamou.gr · www.iatronet.gr · www.zougla.gr
- [● 2 SOURCES] Two‑year event‑free survival was 79.4 % with enfortumab vedotin‑pembrolizumab versus 66.2 % with chemotherapy. www.iatronet.gr · www.zougla.gr
- [● 3 SOURCES] The trial results were published in the New England Journal of Medicine. www.ygeiamou.gr · www.iatronet.gr · www.zougla.gr
- [● 3 SOURCES] The study was conducted by Dr Maria Kaparelou and Prof Thanos Dimopoulos at the Alexandra Hospital, Medical School of the University of Athens (EKPA). www.ygeiamou.gr · www.iatronet.gr · www.zougla.gr
- [● 3 SOURCES] The KEYNOTE‑B15/EV‑304 trial enrolled 808 patients with muscle‑invasive bladder cancer. www.ygeiamou.gr · www.iatronet.gr · www.zougla.gr
- [○ 1 SOURCE] The improvement represented a 47 % reduction in the risk of recurrence, progression or death. www.iatronet.gr